Biohaven Ltd.
Close on Oct 19, 2026
- Market cap
- $1.71B
- P/E (TTM)
- –
- Dividend yield
- –
About Biohaven
Pharmaceutical Preparations, SIC 2834
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes therapies for neurological, immunological, and metabolic conditions. The company advances several clinical-stage drug candidates across multiple therapeutic platforms. Key investigational assets include BHV-1300 and BHV-1400, which are extracellular protein degraders under development for autoimmune diseases such as Graves' disease and IgA nephropathy. It also develops opakalim, a potassium channel activator for epilepsy, and taldefgrobep alfa, an investigational agent targeting obesity and neuromuscular disorders. Biohaven's potential treatments are designed for patients affected by serious central nervous system, autoimmune, and metabolic disorders.
Biohaven controls worldwide rights to substantially all of its product candidates and operates on an international scale. Its clinical research network includes more than 110 global clinical trial sites selected for its focal epilepsy program, alongside clinical evaluations approved in Canada. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Biohaven's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Biohaven Ltd.
- Headquarters
- New Haven, CT
- Address
- 215 Church Street 06510
- Phone
- (203) 404-0410
- Website
- biohaven.com
- Employees
- 274, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- D8
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Stamford, Connecticut
Stock & identifiers
- Ticker
- BHVN
- Exchange
- NYSE
- IPO date
- Sep 23, 2022
- Shares outstanding
- 151M, Aug 6, 2026
- Public float
- $1.04B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1935979
- CUSIP
- G1110E107
- ISIN
- USG1110E1076
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Vlad Coric | Chief Executive Officer, Director | 3,856,784 |
| Kimberly Gentile | SVP, Clinical Operations | 101,513 |
| Warren Karl Volles | Chief Legal Officer | 248,212 |
| George C. Clark | VP, Chief Accounting Officer | 86,978 |
| Bruce Car | Chief Scientific Officer | 40,096 |
| Matthew Buten | Chief Financial Officer | 198,246 |
| John Yetimoglu | Director | 6,250,000 |
| Gregory Bailey | Director | 2,020,071 |
| John W. Childs | Director | 8,088,392 |
| Kishan Mehta | Director | 22,662 |
| Irina Antonijevic | Director | 2,535 |
| Michael Thomas Heffernan | Director | 15,178 |
| Robert J. Hugin | Director | 12,959 |
| Julia P. Gregory | Director | 25,665 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Vlad Coric | $13.50M | -$3.87M | $4.42M | $166 | $152 |
| FY2024 Dr. Vlad Coric | $10.48M | $9.85M | $3.94M | $534 | $113 |
| FY2023 Dr. Vlad Coric | $6.82M | $22.15M | $2.63M | $611 | $112 |
| FY2022 Dr. Vlad Coric | $5.97M | $9.97M | $1.91M | $198 | $104 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“Development and continuous feedback are priorities for our organization, which was comprised of 274 employees as of December 31, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 14, 2022 | Name change | Name changed from Biohaven Research Ltd. to Biohaven Ltd. |
| Aug 10, 2022 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |